RIPK1 and neoplasm: TRIM28 also promotes chemokine-driven myeloid-derived suppressor cell recruitment in the tumor microenvironment by interacting with RIPK1 (receptor interacting serine/threonine kinase 1) and facilitating its K63-linked polyubiquitination, thereby activating the NF-κB signaling pathway.